Foxp3 is correlated with VEGF-C expression and lymphangiogenesis in cervical cancer

Jiabu Tang¹, Zheng Yang², Zhuo Wang², Zhen Li¹, Hongmei Li¹, Jinbao Yin¹, Min Deng³*, Wei Zhu¹* and Chao Zeng¹*

Abstract

**Background:** Recent observations revealed Foxp3 participated in the development of cervical cancer. Furthermore, Foxp3 has a vital function in the lymphatic metastasis of cervical cancer. However, it is unclear whether Foxp3 is correlated with lymphangiogenesis of cervical cancer.

**Methods:** In this experiment, expression of Foxp3 and VEGF-C was detected in 50 cervical cancer samples by immunohistochemistry. In addition, we evaluated the association between Foxp3 and VEGF-C expression and lymphangiogenesis of cervical cancer evaluated by lymphatic vessel density.

**Results:** These data demonstrate Foxp3 is positively correlated with VEGF-C expression. Furthermore, Foxp3 is associated with lymphangiogenesis of cervical cancer.

**Conclusions:** These results revealed Foxp3 play an important role in lymphangiogenesis of cervical cancer.

**Trial registration:** Guangdong Medical University, PJ2013049

**Keywords:** Foxp3, Cervical cancer, Lymphangiogenesis

Background

Cervical cancer is the second common malignant tumor in female [1]. As cervical cancer is characterized by few clinical manifestations, it is hard to detect their existence in early stage. Hence, the prognosis of cervical cancer in advanced stage is unsatisfactory. A well-defined etiology of cervical cancer is infected by high-risk human papillomavirus (HPV). However, the underlying pathogenesis of the disease requires further research.

FOX3, a member of a forkhead box proteins family, contained a winged helix DNA-binding domain. Human Foxp3 gene is located at Xp1 1.23, and it plays as a controller of the function of regulatory T-cells, which have a vital role in the process of forming microenvironment with immunosuppressive tumor [2–7]. Recent studies report Foxp3 is not only presented in Treg cells but also expressed in a variety of cancer cells [8–16]. For example, Foxp3 is over-expressed in breast [12], gastric [14], and thyroid cancer [13], and it also closely correlated with progression and prognosis of these cancers. Luo et al. revealed Foxp3 participated in advancement of normal cervical tissues to cervical cancer [17]. Furthermore, Foxp3 had a significant role in facilitating lymphatic metastasis of cervical cancer [17, 18], and high Foxp3 expression in the cervical cancer predicted a poor prognosis [17].

Recently, Sasahira et al. revealed Foxc2 regulated angiogenesis and lymphangiogenesis in oral squamous cell carcinoma [19]. Foxc1 and Foxc2 are required for lymphatic sprouting during vascular development [20]. Nevertheless, until now, no research has reported the association of Foxp3 expression with lymphangiogenesis of cervical cancer. In this experiment, we investigated the association of Foxp3 with VEGF-C expression and the role of Foxp3 in lymphangiogenesis of cervical cancer.

**Methods**

**Patients and tissue samples**

In the assay, 50 cervical cancer samples were obtained from un-selected patients at Department of Pathology,
the First Affiliated hospital of Sun Yat-sen University. More details of clinical and pathological information about these patients are listed in Table 1. In these samples, 42 cases were squamous cancer and 8 cases were adenocancer. Thirty-four cases had no lymph node metastasis, and 16 cases present lymph node metastasis. The study was approved by Institutional Research Ethics Board of Guangdong Medical University.

**Immunohistochemistry**
Paraffin block was cut into 4-μm sections and treated by routine skill. After microwaved in citrate buffer for 5 min, the slides were incubated with Foxp3 (ab10563, Abcam, USA), VEGF-C (sc-374,628, Santa Cruz, CA), and D2-40 (MAB-0567, Maxim-Bio, Fuzhou, China) at room temperature respectively. Then, the sections were incubated with a secondary antibody (MaximBio Company, Fuzhou, China). Labeling was monitored by diaminobenzidine (Maxim-Bio Company). At last, hematoxylin was used to stain the sections.

**IHC evaluation**
Foxp3 and VEGF-C expression was scored in accordance with the intensity (0, no staining; 1, weak staining; 2, moderate staining; 3, strong staining) and extent staining of cervical cancer cells that were stained (0, no stained; 1, < 10% cervical cancer cells stained; 2, 10–50% cervical cancer cells stained; 3, > 50% cervical cancer cells stained; 4, > 75% cervical cancer cells stained). If the data of multiplication between staining intensity and the extent of positive cervical cancer cells is ≥ 2, it is regarded as positive (+). Finally, in five unselected areas of a 1-mm² field, the number of lymphatic vessels was accumulated, then calculated the average.

**Statistical analysis**
All statistical analyses were done by SPSS 13.0 (SPSS, Inc., Chicago, IL). χ² test was used to evaluate the association of Foxp3 and VEGF-C with clinicopathological parameters. The relation of Foxp3 with VEGF-C was evaluated by Fisher’s exact. The difference was statistical when the P value is < 0.05.

**Results**
Expression of Foxp3 and VEGF-C in cervical cancer
Immunohistochemical staining of Foxp3 was performed in 50 cervical cancer cases. After evaluating by two pathologists, Foxp3 expression was observed in 66% (33/50) cervical cancer tissues. As shown in Fig. 1a–c and Fig. 2a–d, Foxp3 was found not only in nuclear of lymphocytes but also in cytoplasm of cervical cancer cells. Similarly, VEGF-C was also immunostained in the cytoplasm of the cervical cancer cells (Fig. 1d–f; Fig. 2e–h).

Table 1 demonstrates the association between Foxp3 expression and clinicopathological factors. Expression of Foxp3 was positive in 87.5% (14/16) cases that had

| Clinical parameter          | Foxp3 expression | P value | VEGF-C expression | P value |
|----------------------------|------------------|---------|-------------------|---------|
|                            | Positive (%)     |         |                  |         |
| Age (year)                 | Positive (%)     | Negative (%) | P value | Positive (%) | Negative (%) | P value |
| < 50                       | 14 (28)          | 10 (20) | 0.373             | 20 (40) | 4 (8) | 0.327 |
| ≥ 50                       | 19 (38)          | 7 (14)  | 1.000             | 18 (36) | 8 (16) | 0.183 |
| Differentiation            |                  |         |                   |         |
| High + moderate            | 17(34)           | 8 (16)  | 0.009             | 23 (46) | 4 (8) | 0.624 |
| Low                        | 16(32)           | 9 (18)  |                   | 15 (30) | 8 (16) | 0.082 |
| Tumor size                 |                  |         |                   |         |
| < 4 cm                     | 12 (24)          | 9 (18)  | 0.102             | 5 (10)  |       | 0.027 |
| ≥ 4 cm                     | 21 (42)          | 8 (16)  |                   | 7 (14)  |       |       |
| Histological type          |                  |         |                   |         |
| Squamous carcinoma         | 30 (60)          | 12 (24) |                   | 34 (68) | 8 (16) |       |
| Adenocarcinoma             | 3 (6)            | 5 (10)  | 0.009             | 4 (8)   | 4 (8) |       |
| Clinical stage             |                  |         |                   |         |
| I + II                     | 19(38)           | 16 (32) |                   | 30(60)  | 5 (10) |       |
| III + IV                   | 14(28)           | 1 (2)   |                   | 8 (16)  | 7 (14) |       |
| Lymph node metastasis      |                  |         |                   |         |
| Absent                     | 19(38)           | 15 (30) |                   | 23 (46) | 11 (22) |       |
| Present                    | 14(28)           | 2 (4)   | 0.026             | 15 (30) | 1 (2) | 0.042 |
lymph node metastasis, and the positive rate was significantly higher than the samples with the absence of lymph node metastasis (55.9%, 19/34). Furthermore, statistical analysis demonstrates that Foxp3 immunoreactivity is associated with some clinicopathological factors, such as clinical stage and lymph node metastasis (all \( P < 0.05 \)). However, there was no significant relation between Foxp3 expression and the other clinical parameters, including age, tumor size, and histological type (all \( P > 0.05 \)). On the other hand, VEGF-C immunoreactivity was observed in 76.0% samples (38/50). As suggested in Table 1, VEGF-C expression had a significant association with cases that presented lymph node metastasis (\( P < 0.05 \)).

**Comparison of Foxp3 and VEGF-C expression**

Both Foxp3 and VEGF-C had immunoreactivity in 31 samples. On the other hand, neither Foxp3 nor VEGF-C was expressed in 10 samples. Only Foxp3 was expressed in 2 samples, whereas VEGF-C alone was expressed in 7 samples (Table 2). These results indicated that Foxp3 expression was significantly associated with VEGF-C expression (\( P < 0.05 \)).
Expression of Foxp3 and VEGF-C predicts lymphangiogenesis of cervical cancer

In this experiment, D2-40 was utilized to assess lymphatic vessel density (LVD) in cervical cancer tissues. As shown in Table 3, Foxp3-positive cases had more lymphatic vessel than Foxp3-negative cases (11.25 ± 3.16 VS 4.14 ± 2.76). Similarly, cases with VEGF-C staining had more lymphatic vessel compared with cases that had no VEGF-C expression (14.67 ± 4.52 vs 5.32 ± 2.27). Notably, samples that combined with Foxp3 expression and VEGF-C expression had the highest lymph vessel (16.83 ± 5.29; Fig. 2).

Discussion

Foxp3, a member of the FOX protein family, is a forkhead (FKH) box transcription factor. It contains a DNA-binding FKH box domain which plays as a transcriptional activator and repressor of specific genes. As known to all, Foxp3 is widely known for its function in the development of immunoregulatory T cells [21]. Recently, it has been discovered that abnormal Foxp3 expression is associated with a series of cancers, such as prostate [22], ovary [16], and breast cancer [12].

Extrinsic expression of Foxp3 inhibits proliferation and induces apoptosis of gastric cancer cells by activating ADP-ribose polymerase1 (PARP), caspase-3 and caspase-9 [23]. Moreover, Tan et al. reported Foxp3 over-expression significantly reduced the proliferation of melanoma cells in vitro and in vivo [8]. These findings indicated that Foxp3 might act as a tumor suppressor gene. Conversely, high Foxp3 expression of the colorectal cancer cells was correlated with unfavorable prognosis compared with cases that had low Foxp3 expression [24]. Similarly, our data suggested Foxp3 expression is correlated with higher clinical stage and lymph node metastasis. This result demonstrated Foxp3 might be involved in lymph node metastasis of cervical cancer.

Interestingly, FOXP3 expression in breast cancer cells was correlated with high Ki-67 index, indicating high proliferative activity of FOXP3-positive tumors. Merlo et al. also demonstrated increased Ki-67 staining in FOXP3-mutated mammary cells. These results indicated that FOXP3 expression could promote proliferation of cancer cells. However, in our study, there was no relation between Foxp3 expression and tumor size. This discrepancy is attributed to different tumor types or absence of cell experiment.

The current study, for the first time, revealed the role of Foxp3 in lymphangiogenesis of cervical cancer. Firstly, we found Foxp3-positive cases had more lymphatic vessel than Foxp3-negative cases. VEGF-C is essential for most lymphangiogenic processes by activating the vascular endothelial growth factor receptors VEGFR-3 and VEGFR-2 [25]. Then, taking into account the critical role of VEGF-C in lymphangiogenesis, we evaluated the correlation between Foxp3 and VEGF-C expression. In this study, our findings suggest Foxp3 had a significant positive correlation with VEGF-C in cervical cancer.

Conclusions

The present assay shows that Foxp3 expression is associated with advancement of cervical cancer and lymph node metastasis. More importantly, Foxp3 might promote lymphatic vessel formation in cervical cancer correlated with VEGF-C expression. Although further studies are needed to elucidate the molecular mechanism of Foxp3 in lymphangiogenesis of cervical cancer, the present assay will provide new insights into the lymph node metastasis of cervical cancer.

Abbreviations

HPV: High-risk human papillomavirus; LVD: Lymphatic vessel density

Acknowledgements

Not applicable.

Funding

This work was supported by the National Natural Science Foundation of China (grant no. 81302245).

Availability of data and materials

None.

Authors’ contributions

CZ, JBT, and ZW designed the experiments, analyzed data, and prepared the manuscript. ZY, ZL, JBY, WZ, and HML performed the experiments. All authors read and approved the final manuscript.

Ethics approval and consent to participate

This study was approved by the Medical Ethics Committee of Guangdong Medical University, Guangdong, China.

Consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1Department of Pathology, Guangdong Medical University, 1 Xincheng Road, Dongguan 523808, China. 2Department of Pathology, The First Affiliated Hospital of Sun Yat-sen University, Zhongshan 2nd Road 74, Guangzhou 510080, China. 3Cancer Hospital and Cancer Research Institute, Guangzhou Medical University, Guangzhou 510095, China.

Received: 26 March 2017 Accepted: 7 August 2017
Published online: 18 September 2017

References
1. Parkin D, Bray F. The burden of HPV-related cancers. Vaccine. 2006;24:511–5.
2. Kerdiles YM, Stone EL, Beisner DR, et al. Foxo transcription factors control regulatory T cell development and function. Immunity. 2010;33:890–904.
3. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3 regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10:490–500.
4. Hori S, Sakaguchi S. Foxp3: a critical regulator of the development and function of regulatory T cells. Microbes Infect. 2004;6:745–51.
5. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science. 2003;299:1057–61.
6. Sasai K, Tanaka F, Mimori K, et al. Prognostic value of tumor-infiltrating FOXP3+ regulatory T cells in patients with hepatocellular cancer. Eur J Surg Oncol. 2008;34:173–9.
7. Hiraoa N, Onozato K, Kosuge T. Prevalence of FOXP3+ regulatory T cells increases during the progression of pancreatic ductal adenocarcinoma and its premalignant lesions. Clin Cancer Res. 2006;12:5423–34.
8. Tan B, Anaka M, Deb S, et al. FOXP3 over-expression inhibits melanoma tumorigenesis via effects on proliferation and apoptosis. Oncotarget. 2014;5:264–76.
9. Ladoire S, Arnould L, Mignot G, et al. Presence of Foxp3 expression in tumor cells predicts better survival in HER2-overexpressing breast cancer patients treated with neoadjuvant chemotherapy. Breast Cancer Res Treat. 2011;125:65–72.
10. Karanikas V, Speletas M, Zamanakou M, et al. Foxp3 expression in human cancer cells. J Transl Med. 2008;6:19.
11. Zuo T, Liu R, Zhang H, et al. FOXP3 is a novel transcriptional repressor for the breast cancer oncogene SKP2. J Clin Invest. 2007;117:3765–73.
12. Merlo A, Casalini P, Carcangiu ML, et al. FOXP3 expression and overall survival in breast cancer. J Clin Oncol. 2009;27:1746–52.
13. Cunha LL, Morari EC, Nonogaki S, et al. Foxp3 expression is associated with aggressiveness in differentiated thyroid cancers. Clinics. 2012;67:483–8.
14. Wang LH, Su L, Wang JT. Correlation between elevated FOXP3 expression and increase lymph node metastasis of gastric cancer. Chin Med J. 2010;123:3545–9.
15. Tao H, Mimura Y, Aoe K, Kobayashi S, et al. Prognostic potential of FOXP3 expression in non-small cell lung cancer cells combined with tumor-infiltrating regulatory T cells. Lung Cancer. 2012;75:101.
16. Zhang HY, Sun H. Up-regulation of Foxp3 inhibits cell proliferation, migration and invasion in epithelial ovarian cancer. Cancer Lett. 2010;289:791–7.
17. Luo Q, Zhang S, Wei H, et al. Roles of Foxp3 in the occurrence and development of cervical cancer. Int J Clin Exp Pathol. 2015;8:8717–30.
18. Zeng C, Yao Y, Je W, et al. Up-regulation of Foxp3 participates in progression of cervical cancer. Cancer Immunol Immunother. 2013;62:481–7.
19. Sasahira T, Ueda N, Yamamoto K, et al. Prox1 and FOXC2 act as regulators of lymphangiogenesis and angiogenesis in oral squamous cell carcinoma. PLoS One. 2014;9:e902534.
20. Seo S, Fujita H, Nakano A, et al. The forkhead transcription factors, Foxc1 and Foxc2, are required for arterial specification and lymphatic sprouting during vascular development. Dev Biol. 2006;294:458–70.
21. Fontenot JD, Rasmussen JP, Williams LM, et al. Regulatory T cell lineage specification by the forkhead transcription factor foxp3. Immunity. 2005;22:329–41.
22. Wang L, Liu R, Li W, et al. Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. Cancer Cell. 2009;16:336–46.
23. Ma GF, Chen SY, Sun ZR, et al. FOXP3 inhibits proliferation and induces apoptosis of gastric cancer cells by activating the apoptotic signaling pathway. Biochem Biophys Res Commun. 2013;430:804–9.
24. Kim M, Grimmig T, Grimm M, et al. Expression of Foxp3 in colorectal cancer but not in Treg cells correlates with disease progression in patients with colorectal cancer. PLoS One. 2013;8:e53630.
25. Krebs R, Jettsch M. The lymphangiogenic growth factors VEGF-C and VEGF-D part 2: the role of lymphangiogenic growth factors VEGF-C and VEGF-D in lymphatic disorders. LymphForsch. 2013;1796–104.

Submit your next manuscript to BioMed Central
and we will help you at every step:
• We accept pre-submission inquiries
• Our selector tool helps you to find the most relevant journal
• We provide round the clock customer support
• Convenient online submission
• Thorough peer review
• Inclusion in PubMed and all major indexing services
• Maximum visibility for your research

Submit your manuscript at www.biomedcentral.com/submit